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Dupuytren’s contracture (DC) is a benign fibroproliferative disease causing fibrot-
ic nodules and fascial cords with resultant debilitating flexion contracture deformi-
ties. The present study was designed to characterize pro-inflammatory cytokines and 
growth factors involved in the genesis, progression and recurrence of the disease to 
optimize therapeutic agents and strategies for controlling Dupuytren’s disease. The 
expression of pro-inflammatory cytokines and other growth factors was detected by 
immunohistochemistry and immunofluorescence in the fibrotic nodules and normal 
palmar fascia resected respectively from patients affected by Dupuytren’s contracture 
and Carpal Tunnel Syndrome (as negative controls). RT-PCR analysis was performed 
to quantify the expression of TGF-β1, IL-1β and VEGFa in the myofibroblasts and 
fibroblasts isolated from Dupuytren’s nodules. Histological analysis showed the high 
cellularity and rate of proliferation of Dupuytren’s tissue with the presence of myofi-
broblastic isotypes. Our data showed the strong expression of TGF-β1, IL-1β and 
VEGFa in Dupuytren’s fibromatosis nodules suggesting a direct role of these mark-
ers in the onset, progression and recurrence of the disease. Our observations suggest 
that TGF-β1, IL-1β and VEGFa may be considered potential therapeutic targets in the 
treatment of Dupuytren’s disease. Moreover, a new innovative therapy may be repre-
sented by the combined use of specific inhibitors of these growth factors.
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